Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a pill and a vaccine stop STIs in High-Risk men?

NCT ID NCT04597424

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two strategies to prevent sexually transmitted infections (STIs) in men who have sex with men and already take HIV PrEP. One group took doxycycline pills after unprotected sex, and another group received a meningitis vaccine (Bexsero). The goal was to see if these approaches could reduce new cases of chlamydia, syphilis, and gonorrhea. Over 550 men took part in this completed Phase 3 trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline and Bexsero® vaccine
What this could lead to
If it works, this could offer a new way to prevent bacterial STIs in high-risk groups, reducing infections like chlamydia, syphilis, and gonorrhea.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all populations. Doxycycline overuse could lead to antibiotic resistance, and the vaccine may not protect against all gonorrhea strains.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

556 people

The number who actually took part.

Started

Jan 2021

Finished

Apr 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Mens who have sex with mens (MSM) enrolled in the ANRS PREVENIR study. * At least 6-month experience with PrEP (within the ANRS PREVENIR study or before starting the ANRS PREVENIR study). * No clinical manifestation of primary HIV infection and no symptom of bacterial STI (chlamydia, gonorrhea, M. genitalium or syphilis). * History of documented bacterial STI with at least one episode in the last 12 months. * Participants who agree to sign the information and consent form specific to this study. * Valid health insurance (State medical aid (AME) is not health insurance). Exclusion Criteria: * Syphilis diagnosed prior to inclusion without serologic evidence of cure (cure is defined as decreased by at least 4-fold of the non-treponemal antibody titer \[Venereal Disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR)\] relative to the titer at initiation of treatment of syphilis). * HIV infection. * Previous vaccination with Bexsero® or any other meningococcal B vaccine. * Vaccination during the 4 weeks (28 days) preceding the first vaccination of the study. * Previous vaccination with an experimental vaccine in the previous 5 years. * Systemic treatment with retinoids : isotretinoin (Acnetrait®, Procuta®, Curacné®, Contracné®, …). * Treatment with enzyme-inducing anticonvulsants (carbamazepine, phenobarbital, phenytoin, ….). * Participant who has received immunoglobulins, a transfusion of blood or blood derivatives in the last 3 months. * Known or suspected congenital or acquired immunodeficiency; immunosuppressive treatment in the last 6 months, such as cancer chemotherapy or radiotherapy; long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks in the last 3 months) * Known allergy to antibiotics of the tetracycline family. * Known allergy to any component of the Bexsero® vaccine. * Known allergy to any component of the doxycycline pill. * Known allergy to latex (contained in the vaccine cap). * Thrombocytopenia or any other known coagulation disorder, which would be a contraindication to an intramuscular injection of Bexsero® vaccine. * Documented oesophageal lesion * Acute respiratory infection or severe acute febrile illness or systemic reaction that may present a significant risk if vaccinated in the month prior to inclusion. * Any condition (clinical) that, in the investigator's opinion, would contraindicate intramuscular vaccination and blood sampling. * Oral Anticoagulant treatment. * Continuous treatment with doxycycline at inclusion. * Vitamin A treatment in case of intake of 10 000 international unit or more. * Participation in another research including an exclusion period still in progress at the time of inclusion. * Under guardianship or curator, or deprived of liberty by a judicial or administrative decision.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial sexually transmitted infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Bichat

    Paris, 75000, France

  • Hôpital Européen Georges Pompidou

    Paris, 75908, France

  • Hôpital Hôtel Dieu

    Paris, 75181, France

  • Hôpital Necker-Enfants Malades

    Paris, 75743, France

  • Hôpital Pitié-Salpétrière

    Paris, 75651, France

  • Hôpital Saint-Antoine

    Paris, 75571, France

  • Hôpital Saint-Louis

    Paris, 75475, France

  • Hôpital Tenon

    Paris, 75970, France

  • Hôpital pitié Salpetrière

    Paris, 75651, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.